Fig. 4. 2130-1-0114-112 provides in vivo prophylactic protection against SARS-CoV-2 variants.
a–i, Eight-week-old female K18-hACE2 mice were administered 100 μg (approximately 5 mg kg−1) of the indicated monoclonal antibody treatment by intraperitoneal injection 1 day before intranasal inoculation with 104 focus-forming units (FFU) of WA1/2020 D614G (a,d,g), Omicron BA.1.1 (b,e,h) or Omicron BA.5 (c,f,i). Tissues were collected 4 days after inoculation. Viral RNA levels in the lungs (a–c), nasal turbinates (d–f) and nasal washes (g–i) were determined by RT–qPCR (lines indicate median of log10 values); n = 9 (WA1/2020 D614G and BA.1.1 isotype control groups) or 10 (all others) mice per group, from two experiments. The limit of assay detection is shown as a horizontal dotted line. Statistical comparisons between groups were by Kruskal–Wallis ANOVA with Dunn’s multiple comparisons post-test; P values are as listed or not significant (NS) if P > 0.05. All analyses were conducted in GraphPad Prism.